Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company that entered the public markets in 2018 through a business combination with Avista Healthcare Public Acquisition Corp., a blank-check vehicle sponsored by Avista Capital Holdings. The company operates in the healthcare sector, focused on advanced wound care and surgical biologics products serving providers across the United States. Organogenesis filed a Form 10-Q with the SEC on November 6, 2025, representing its most recent quarterly disclosure as a post-merger public company. For full sponsor profiles, filing histories, and post-merger operating data on Organogenesis and hundreds of other SPAC transactions, sign up for a SpacDesk account at spacdesk.com.